pages as needed to provide the required information Organization of Neurosurgery/Neuro-oncology of Pathology and Immunology 129 Page in the format shown below. Role on Project Principal Investigator Co-Principal Investigator Continuation Format Project 1 DD DETAILED BUDGET DIRECT PERSONNEL (Applicant organization NAME Hideho Okada William F. Chambers Fumihiko Nishimura Junichi Eguchi Jill Dusak 1-Feb-04 Principal Investigator/Program Director (Lest, first, middle): Storkus, Walter, Ph.D. FOR INITIAL BUDGET PERIOD COSTS ONLY FR1O2/M1/2004 I THRO1U1/G3H0/2005 only) % DOLLAR AMOUNT REQUESTED _mitcents) TYPE EFFORT INST. ROLE ON APPT. ON 6ASE SALARY FRINGE PROJECT (months) PROJ. SALARY REQUESTED BENEFITS* TOTALS Principal Investigator 12 25% 82,752 20,688 4,758 25,446 Co-PI 12 15% 100,468 15,070 3,466 18,536 Research Associate 12 50% 26,072 13,036 4,797 17,833 Research Associate 12 50% 14,600 7,300 2,686 9,986 Research Technician 12 100% 26,554 26,554 9,772 36,326 *Fringe Benefits are calculated at 23% for medical faculty, 24% for non-medical faculty, and 36. 8% for staff. SUBTOTALS 82,648 25,479 108,127 I CONSULTANT COSTS 0 EQUIPMENT (itemize) 0 SUPPLIES (Itemize by category) Computer and software 2,000 Pipette tips, Culture Flasks & Plates, Reagents, Media, Serum 13,000 Immunological Assay Reagents 7,000 Wild Type Mice ($15/animal x 40 animals/month x 12 months) 7,920 Gene Knockout Mice (appx $50/animal x90 animals/year) 5,220 35,140 TRAVEL One domestictripto scientific meetingforPI 1,500 1,500 0 PATIENT CARE COSTS INPATIENT 0 OUTPAT ENT ALTERATIONS AND RENOVATION5 (Itemize by category) OTHER EXPENSES (Itemize by category) Animal care ($1.50/day/cage x 200 cages x 60.5 [average] days) 15,750 Flow cytometry (3.5 hrs/week @ $50/hour x 50) 8,75O 24,500 SUBTOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD $ 169,267 I CONSORTIUM/CONTRACTUAL DIRECT COSTS COSTS FACILITLES AND ADMINISTRATION COSTS TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD (Item 7a. Face Page) $ 169,267 I I SBIR/STTR Only: FIXED FEE REQUESTED I PHS 398 (Rev. 5/01) (Form Page 4) Page 130 Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Yang, Chenjie; Ruffner, Melanie A; Kim, Seon-Hee et al. (2012) Plasma-derived MHC class II+ exosomes from tumor-bearing mice suppress tumor antigen-specific immune responses. Eur J Immunol 42:1778-84
Reay, J; Gambotto, A; Robbins, P D (2012) The antitumor effects of adenoviral-mediated, intratumoral delivery of interleukin 23 require endogenous IL-12. Cancer Gene Ther 19:135-43
Zhao, Xi; Bose, Anamika; Komita, Hideo et al. (2012) Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 188:1782-8
Rao, Aparna; Taylor, Jennifer L; Chi-Sabins, Nina et al. (2012) Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res 72:3196-206
Qu, Yanyan; Chen, Lu; Lowe, Devin B et al. (2012) Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. Mol Ther 20:644-51
Qu, Y; Taylor, J L; Bose, A et al. (2011) Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther 18:663-73
Lowe, Devin B; Storkus, Walter J (2011) Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy 3:1265-74
Zhao, Xi; Bose, Anamika; Komita, Hideo et al. (2011) Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther 19:805-14
Zhu, Xinmei; Fallert-Junecko, Beth A; Fujita, Mitsugu et al. (2010) Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 59:1401-9
Lipscomb, Michael W; Taylor, Jennifer L; Goldbach, Cristina J et al. (2010) DC expressing transgene Foxp3 are regulatory APC. Eur J Immunol 40:480-93

Showing the most recent 10 out of 31 publications